Expanding breast cancer clinical trials and testing new treatments at Mayo Clinic
Developing, Implementing and Supporting NCI Clinical Trials and the National Cancer Trials Network (NCTN) in Breast Cancer and Developmental Therapeutics- A 5 Year Plan
This project will support and run clinical trials testing new therapies for people with HER2-positive or endocrine-resistant breast cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11191464 on NIH RePORTER |
What this research studies
You would be joining an effort at Mayo Clinic to run and support National Cancer Institute trial programs that bring new drugs and combinations to patients with HER2-positive and endocrine-resistant breast cancer. The team focuses on overcoming drug resistance and personalizing systemic treatment for early-stage HER2+ disease by opening trials through the National Cancer Trials Network. Trials are designed and led by clinician‑researchers and often involve collaborations across multiple sites, with input from patient advocates to improve care and access. Participation could involve testing targeted drugs, combination therapies, and treatment strategies tailored to tumor features.
Who could benefit from this research
Good fit: Ideal candidates are people with HER2-positive breast cancer, tumors that are resistant to endocrine therapy, or patients with early-stage HER2+ disease considering systemic treatment options.
Not a fit: People without breast cancer or those with breast cancer subtypes that are not HER2-positive or not endocrine-resistant are unlikely to benefit directly from these trials.
Why it matters
Potential benefit: If successful, this work could expand access to newer targeted treatments and better match therapies to people with HER2-positive or endocrine-resistant breast cancer.
How similar studies have performed: HER2-targeted treatments and many NCI-sponsored trials have improved outcomes for HER2+ disease, though specific new combinations remain experimental and are being tested.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: O'sullivan, Ciara C — Mayo Clinic Rochester
- Study coordinator: O'sullivan, Ciara C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.